Solasia to initiate clinical trials in China for its Transdermal patch product

Solasia, a Japan-headquartered company, has received a nod from SFDA to conduct clinical trials in China for Sancuso. Sancuso is a transdermal patch product for the treatment of chemotherapy-induced
nausea and vomiting. Solasia in-licensed rights to Sancuso for Southeast Asia in 2008 from, ProStrakan - the UK subsidiary of Kyowa Hakko Kirin. Kyowa acquired Prostrakan in April 2011.

Sancuso is already approved in the US and Europe, while it is under development or in commercialisation through ProStrakan's partners in:

• Asia & Pacific (Invida)
• Canada (Paladin Labs)
• China and other Asian countries (Solasia)
• Middle East & Africa (NewBridge)
• South Korea (LG Life Sciences)

Solasia will begin a trial of the product immediately and expects to file a New Drug Application in China during Q4 of 2013.

Enter your email address:


Delivered by FeedBurner